Genmab A/S
Bispecific antibodies against CD3 and CD20

Last updated:

Abstract:

Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.

Status:
Grant
Type:

Utility

Filling date:

8 Jan 2016

Issue date:

28 Jan 2020